Tag Archives: Tuberculosis

Outlook “Gloomy” for TB Investment

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
Posted in Emerging Markets, Global, Strategy | Also tagged , , , , | Leave a comment

US Cuts Could Jeopardize Global Health Innovations, Says Report

Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
Posted in Events | Also tagged , , , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts […]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D | Also tagged , , , , , , , , , | Leave a comment

A Critical Path to New TB Treatments

Image via Wikipedia FDA Commissioner Margaret Hamburg announced, on Thursday, a new joint initiative between industry, FDA, and non-profit organizations designed to fast-track modern combination treatments for tuberculosis. Where once it took more than two decades to create new therapies for TB, this collaboration is expected to produce working treatments in less than six years, […]
Posted in R&D | Also tagged , , , , , , | 2 Comments
  • Categories

  • Meta